230 related articles for article (PubMed ID: 12434103)
1. [Clinical response of an atypical glucagonoma treated with a long-acting somatostatin analog].
Bouin M; Aoust LD
Gastroenterol Clin Biol; 2002 Oct; 26(10):926-9. PubMed ID: 12434103
[TBL] [Abstract][Full Text] [Related]
2. [Malignant glucagonoma: an uncommon cause of new onset diabetes].
Guerrero Vázquez R; Oliva Rodríguez R; Cuenca Cuenca JI; Sánchez Alberdi F; Navarro González E
Endocrinol Nutr; 2011 Apr; 58(4):199-201. PubMed ID: 21334267
[No Abstract] [Full Text] [Related]
3. Successful treatment of canine necrolytic migratory erythema (superficial necrolytic dermatitis) due to metastatic glucagonoma with octreotide.
Oberkirchner U; Linder KE; Zadrozny L; Olivry T
Vet Dermatol; 2010 Oct; 21(5):510-6. PubMed ID: 20500495
[TBL] [Abstract][Full Text] [Related]
4. [A case of pancreatic glucagonoma].
Simonenko VB; Dulin PA; Beliaev LB; Makanin MA; Dem'ianenko AV; Zykova AA; Zhuravleva SI; Kolesnikova VN
Klin Med (Mosk); 2007; 85(8):67-70. PubMed ID: 17926496
[TBL] [Abstract][Full Text] [Related]
5. Use of a somatostatin analog (SMS 201-995) in the glucagonoma syndrome.
Altimari AF; Bhoopalam N; O'Dorsio T; Lange CL; Sandberg L; Prinz RA
Surgery; 1986 Dec; 100(6):989-96. PubMed ID: 2878500
[TBL] [Abstract][Full Text] [Related]
6. Somatostatin analogue in treatment of coexisting glucagonoma and pancreatic pseudocyst: dissociation of responses.
Moattari AR; Cho K; Vinik AI
Surgery; 1990 Sep; 108(3):581-7. PubMed ID: 2168587
[TBL] [Abstract][Full Text] [Related]
7. Glucagonoma with necrolytic migratory erythema exhibiting responsiveness to subcutaneous octreotide injections.
Lo CH; Ho CL; Shih YL
QJM; 2014 Feb; 107(2):157-8. PubMed ID: 23389434
[No Abstract] [Full Text] [Related]
8. Regression of a large malignant gastrinoma on treatment with Sandostatin LAR: a case report.
Granberg D; Jacobsson H; Oberg K; Gustavsson J; Lehtihet M
Digestion; 2008; 77(2):92-5. PubMed ID: 18376130
[TBL] [Abstract][Full Text] [Related]
9. Rapid improvement of glucagonoma-related necrolytic migratory erythema with octreotide.
Kimbara S; Fujiwara Y; Toyoda M; Chayahara N; Imamura Y; Kiyota N; Mukohara T; Fukunaga A; Oka M; Nishigori C; Minami H
Clin J Gastroenterol; 2014 Jun; 7(3):255-9. PubMed ID: 26183746
[TBL] [Abstract][Full Text] [Related]
10. Treatment of inoperable glucagonoma with the long-acting somatostatin analogue SMS 201-995.
Boden G; Ryan IG; Eisenschmid BL; Shelmet JJ; Owen OE
N Engl J Med; 1986 Jun; 314(26):1686-9. PubMed ID: 2872592
[No Abstract] [Full Text] [Related]
11. Somatostatin analog octreotide LAR in gastro-entero-pancreatic tumors.
Oberg K
Expert Rev Anticancer Ther; 2009 May; 9(5):557-66. PubMed ID: 19445573
[TBL] [Abstract][Full Text] [Related]
12. Malignant glucagonoma. New options of treatment.
Appetecchia M; Ferretti E; Carducci M; Izzo F; Carpanese L; Marandino F; Terzoli E
J Exp Clin Cancer Res; 2006 Mar; 25(1):135-9. PubMed ID: 16761630
[TBL] [Abstract][Full Text] [Related]
13. Dermatitis, glossitis, stomatitis, cheilitis, anemia and weight loss: a classic presentation of pancreatic glucagonoma.
Povoski SP; Zaman SA; Ducatman BS; McFadden DW
W V Med J; 2002; 98(1):12-4. PubMed ID: 11941895
[TBL] [Abstract][Full Text] [Related]
14. Necrolytic migratory erythema associated with hyperglucagonemia and neuroendocrine hepatic tumors.
Marko PB; Miljković J; Zemljic TG
Acta Dermatovenerol Alp Pannonica Adriat; 2005 Dec; 14(4):161-4, 166. PubMed ID: 16435046
[TBL] [Abstract][Full Text] [Related]
15. Clinical experience in diagnosis and treatment of glucagonoma syndrome.
Zhang M; Xu X; Shen Y; Hu ZH; Wu LM; Zheng SS
Hepatobiliary Pancreat Dis Int; 2004 Aug; 3(3):473-5. PubMed ID: 15313692
[TBL] [Abstract][Full Text] [Related]
16. [Recurrent glucagonoma 20 years after surgical resection].
Pautrat K; Bretagnol F; de Muret A; de Calan L
Gastroenterol Clin Biol; 2003 Dec; 27(12):1163-5. PubMed ID: 14770122
[TBL] [Abstract][Full Text] [Related]
17. [Glucagonoma: evolution and treatment].
Carvajal C; Azabache V; Lobos P; Ibarra A
Rev Med Chil; 2002 Jun; 130(6):671-6. PubMed ID: 12194691
[TBL] [Abstract][Full Text] [Related]
18. Predictive factors of efficacy of the somatostatin analogue octreotide as first line therapy for advanced pancreatic endocrine carcinoma.
Butturini G; Bettini R; Missiaglia E; Mantovani W; Dalai I; Capelli P; Ferdeghini M; Pederzoli P; Scarpa A; Falconi M
Endocr Relat Cancer; 2006 Dec; 13(4):1213-21. PubMed ID: 17158766
[TBL] [Abstract][Full Text] [Related]
19. Rare presentation of endocrine pancreatic tumour: a case of glucagonoma without necrolytic migratory erythema?
Manes G; Pellegrini A; Riccardi F; Uomo G
Ital J Gastroenterol; 1995 Jun; 27(5):248-9. PubMed ID: 8541575
[TBL] [Abstract][Full Text] [Related]
20. [Glucagonoma: case report and literature review].
das Neves MM; Martins Júnior EV; Gaburri AK; Chebli JM; Stávale JN; Herani Filho AK
Arq Gastroenterol; 1996; 33(3):167-72. PubMed ID: 9201330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
